Ulcerative Colitis Market to Grow Positively by 2032, Predicts DelveInsight | Key Companies - Arena, Pfizer, Abivax, InDex, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast
October 24, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ulcerative Colitis Market to Grow Positively by 2032, Predicts DelveInsight | Key Companies - Arena, Pfizer, Abivax, InDex, AbbVie, Boehringer...
A myriad of drugs are in the pipeline for Ulcerative Colitis treatment: DelveInsight
March 30, 2021 20:40 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, March 30, 2021 (GLOBE NEWSWIRE) -- A myriad of drugs are in the pipeline for Ulcerative Colitis treatment: DelveInsight The Ulcerative Colitis drug pipeline is robust with 100+...
Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand
November 23, 2020 08:30 ET
|
Generex Biotechnology Corp.
Memorandum of Understanding (MOU) signed by both partiesNegotiating final contract termsUpfront payment on closingLicensing fees, expenses, and price per dose to be determinedBintai Kinden Corporation...
Generex Biotechnology Announces Corporate Update and Investor Conference Call: Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines - Thursday February 13, 2020 at 11:00 AM EST
February 10, 2020 09:00 ET
|
Generex Biotechnology Corporation
MIRAMAR, Fla., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the...
Generex Declares NEW Dividend RECORD DATE: Monday, February 17, 2020
February 07, 2020 08:30 ET
|
Generex Biotechnology Corporation
PAY DATE: Monday, February 24, 2020EX DATE: Tuesday, February 25, 2020 MIRAMAR, Fla., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”)...
Generex Biotechnology Announces Funding Update
December 05, 2019 10:29 ET
|
Generex Biotechnology Corporation
MIRAMAR, Fla., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB: GNBT) is pleased to announce that the company has finalized agreements to provide significant funding for...
Generex Biotechnology Signs Stock Purchase Agreement to Acquire 51% of ALTuCELL, Inc.
November 25, 2019 08:30 ET
|
Generex Biotechnology Corporation
Closing Scheduled for December 2019Patented AltuCaps® for Microencapsulation of stem cells for autoimmune and inflammatory diseases: Partnering opportunities availableAltsulin® implantable Sertoli...
Generex Biotechnology Provides Fiscal Year Overview
July 10, 2019 09:15 ET
|
Generex Biotechnology Corporation
GNBT Reorganization & TransformationAcquisitions: Olaregen Therapeutix, Regentys, Veneto Assets, Pantheon Medical, MediSource PartnersCompleted 100% Acquisition of HDS (now NuGenerex Diagnostics)...
Global $25.4 Bn Tissue Engineering (Technologies and Therapeutic) Markets, 2015-2018 & 2019-2024: Orthopedics, Musculoskeletal & Spine Applications Corner the Largest Share
July 02, 2019 09:20 ET
|
Research and Markets
Dublin, July 02, 2019 (GLOBE NEWSWIRE) -- The "Tissue Engineering: Technologies and Therapeutic Areas - A Global Market Overview" report has been added to ResearchAndMarkets.com's ...
Reminder: Investor Conference Call Friday June 21st, 2019
June 17, 2019 09:00 ET
|
Generex Biotechnology Corporation
Management to Provide Update on Initiatives & Strategic PlansCall-in Details MIRAMAR, Fla., June 17, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT)...